Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort

<b>Background</b>: Cefiderocol (CFD) is a novel siderophore cephalosporin developed for the treatment of infections involving multidrug-resistant (MDR) Gram-negative bacilli (GNB) infections (1–3). For bone and joint infections (BJIs), the use of CFD is currently neither part of its market authoriza...

Description complète

Détails bibliographiques

Auteurs principaux:	Ava Diarra, Maxime Degrendel, Isabelle Eberl, Tristan Ferry, Karim Jaffal, Lelia Escaut, Antoine Asquier Khati, Nicolas Taar, Johan Courjon, Laurène Deconinck, Benjamin Lefevre, Aurélie Baldolli, Messaline Bermejo, Alexandre Bleibtreu, Vincent Dacquet, Victoire de Lastours, Pierre Gazeau, Romaric Larcher, Pierre Patoz, Olivier Robineau, Nicolas Rouzic, Naomi Sayre, Diana Isabela Costescu Strachinaru, Benjamin Valentin, Heidi Wille, Eric Senneville
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2025-04-01
Collection:	Antibiotics
Sujets:	cefiderocol bone and joint infection Gram-negative bacilli tolerance outcome
Accès en ligne:	https://www.mdpi.com/2079-6382/14/4/388
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!